DBV Technologies

Company snapshot

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives ou

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for DBV Technologies. Not investment advice.

• What is DBV Technologies?

  DBV Technologies is a pharma organization headquartered in CHATILLON, FR. Primary therapeutic focus areas include Peanut allergy, Allergy, Peanut. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTr

• Is DBV Technologies publicly traded?

  DBV Technologies appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does DBV Technologies develop or market?

  We link 7 drug profile(s) where DBV Technologies is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/dbv-technologies#company-drugs.

• What are the latest developments for DBV Technologies?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does DBV Technologies focus on?

  DBV Technologies focuses on Peanut allergy, Allergy, Peanut based on our analysis of their pipeline programs and drug development activities.